Vera Therapeutics, Inc. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Vera Therapeutics, Inc. (VERA) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of -$66.00 thousand as of 2024-03-31, per its 10-Q filed 2024-05-10.
Discontinued › Notes › Debt › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2024-05-10
- 2024-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net -$66.00K.
- 2023-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $123.00K.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2024-03-31 | -$66.00K 10-Q · filed 2024-05-10 |
| 2023-12-31 | $123.00K 10-Q · filed 2024-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |